Phosphatidylinositol-3-kinase as a therapeutic target in melanoma.

ABSTRACT:

Purpose

Phosphatidylinositol-3 kinases (PI3K) are critical for malignant cellular processes including growth, proliferation, and survival, and are targets of drugs in clinical development. We assessed expression of PI3K in melanomas and nevi, and studied associations between PI3K pathway members and in vitro response to a PI3K inhibitor, LY294002.

Experimental design

Using Automated Quantitative Analysis, we quantified expression of p85 and p110alpha subunits in 540 nevi and 523 melanomas. We determined the IC(50) for LY294002 for 11 melanoma cell lines and, using reverse phase protein arrays, assessed the association between levels of PI3K pathway members and sensitivity to LY294002.

Results

p85 and p110alpha tend to be coexpressed (P < 0.0001); expression was higher

SUBMITTER: Aziz SA 

PROVIDER: S-EPMC4431617 | biostudies-literature | 2009 May

REPOSITORIES: biostudies-literature